Search

everythinglearnresearchcommunity

for

Search:↓

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

New small molecule drugs show promise in treating complex skin diseases but need more safety research.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

New treatments for severe alopecia areata show promise but lack standard approval.

Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.

Pharmacists play a crucial role in safe medication use and interdisciplinary collaboration is key to reducing antimicrobial resistance.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Most patients with rheumatoid arthritis continued methotrexate treatment over two years, but those who stopped and restarted experienced more side effects and less improvement.

Upadacitinib effectively treats pyoderma gangrenosum.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Axitinib treatment turned a man's grey hair back to black.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

Ivarmacitinib effectively regrows hair in severe alopecia areata.